Companies: 10,795·Total market cap: $144.5T
Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVSNASDAQHealthcare● Active
$11.18
+$0.06(+0.54%)
Market Cap$940130672
P/E Ratio
52W High$26.95
52W Low$3.55
SEC Filings

Corvus Pharmaceuticals, Inc. (CRVS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001626971 · CRVS · NASDAQ · as of Jun 8, 2026

Filing snapshot

570
Total Filings
4
Latest Form
2026-05-20
Most Recent
2016
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001626971 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-12
Fiscal Year End
Mar 12, 2026
Accession No.
0001104659-26-027047
Primary Document
crvs-20251231x10k.htm
Source: data.sec.gov · CIK 0001626971 · Accession 0001104659-26-027047

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
FORM 8-K
2026-05-14Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
8-KCurrent Report
FORM 8-K
2026-05-14
View
S-8Employee Stock Plan Registration
FORM S-8
2026-05-07
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
FORM 8-K
2026-05-07
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-04-27
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-27
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-24
View
DEF 14AProxy Statement
DEF 14A
2026-04-24
View
8-KCurrent Report
8-K
2026-04-23
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
FORM 8-K
2026-03-13
View
424B5424B5
424B5
2026-03-13
View
S-3ASRS-3ASR
S-3ASR
2026-03-13
View
Showing 1–15 of 351 filingsForm 4 / 144 hidden· 570 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001626971  |  Exchange: NASDAQ · Healthcare

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) has submitted 570 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2016. As a Healthcare sector company with CIK 0001626971, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Corvus Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Corvus Pharmaceuticals, Inc. 10-K was filed on 2026-03-12 for fiscal year ending 2026. Historical CRVS 10-K annual reports are available from 2014 through 2026.

Investors researching Corvus Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

CRVS SEC Filings · 8 questions

Corvus Pharmaceuticals, Inc. (CRVS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 570 filings and access original documents at no cost. Corvus Pharmaceuticals, Inc.'s CIK is 0001626971.

CRVS SEC filingsCorvus Pharmaceuticals, Inc. SEC documentsfind CRVS 10-K